Page 10 - AWA Vol.41-No.5. 1

PoULtry

Study Identifies Optimal Formulation of ZIVO’s

to Mitigate Avian Influenza in Poultry

pioneering biotech/agtech R&D ous testing at the University of Delaware
A company dedicated to develop- reinforce our commitment to develop-
ing therapeutic, medicinal and nutri- ing sustainable, non-antibiotic solutions
tional product candidates derived from for the poultry industry. The insights
proprietary algal cultures, today an- gained from this study show encour-
nounced positive results from its second aging trends and identifying a supe-
collaborative study with the University rior formulation will be instrumental in
of Delaware evaluating the efficacy of guiding our future research and product
several formulations of ZIVO’s proprie- optimization efforts. Given the potential
tary active ingredients in mitigating the lessen disease severity. impact ZIVO’s product can have on miti-
spread of Low Pathogenicity Avian Influ- The second arm focused on the trans- gating avian influenza, a widespread is-
enza (LPAI) virus among poultry. sue in the nation’s large poultry indus-
mission of the virus from infected birds
Building upon the outcomes of the ini- to naïve birds. Notably, the formulation try, we submitted a funding request to
tial study, this second study aimed to consisting of a blend of four distinct the State of Michigan for $5.5 million to
assess and compare the performance algal-derived materials demonstrated a further our research. Additionally, we
of three different ZIVO formulations in slower and less efficient spread of the are applying for a portion of the previ-
both directly challenged and contact- virus. One bird treated with this com- ously announced $100 million Avian In-
exposed birds. The study affirmed ear- bination showed no signs of infection fluenza Poultry Innovation Grand Chal-
lier observations that ZIVO's active in- post-exposure, indicating potential pro- lenge from the USDA," said John Payne,
gredients may positively influence LPAI tective effects. Chairman and CEO of ZIVO Bioscience.
transmission dynamics, while identify- ZIVO Bioscience remains dedicated to
ing the optimal formulation for further Brian Ladman, PhD, Principal Inves- advancing its pipeline of algal-derived
testing. tigator at the University of Delaware's compounds aimed at enhancing poultry
Department of Animal and Food Sci-
In the first arm of the study, which in- health and productivity. The company
volved birds receiving a direct chal- ences, commented, "Any positive trend plans to continue its collaboration with
lenge with LPAI, modest positive trends observed in these early-stage studies is the University of Delaware to further
were observed in viral shedding reduc- very encouraging. Delaying transmis- explore and refine these interventions,
tion among ZIVO-treated groups com- sion, even by a few days, can provide including a larger scale project focused
pared with untreated controls. While significant benefits to poultry produc- on a single formulation in order to de-
these differences did not reach statis- ers by allowing more time to manage termine the reproducibility of the ob-
tical significance, the findings suggest high risk or at-risk flocks effectively." servations from the first two studies.
potential for ZIVO's formulations to "These findings resulting from rigor- Circle 8 on enquiry card

Merck Animal Health receives Positive CVMP opinion for
iNNoVAX®-Nd-iBd-iLt for Use in Chickens

erck Animal Health, known as devastating poultry diseases.
MMSD Animal Health outside of “Merck Animal Health is dedicated to
the United States and Canada, a divi- providing innovations that protect broil-
sion of Merck & Co., Inc., Rahway, N.J., ers, breeders and laying hens from key
USA (NYSE:MRK), today announced to- viral poultry pathogens,” said Maxim
day announced that the European Med- Nakhodko, Global Poultry Business Unit
icines Agency’s Committee for Veteri- Lead at Merck Animal Health. “Today’s
nary Medicinal Products (CVMP) issued positive opinion for the INNOVAX-ND-
a positive opinion for the INNOVAX®- IBD-ILT vaccine brings us closer to of-
ND-IBD-ILT vaccine. fering a single vaccine that targets four
If approved, this will be the only sin- different pathogens using our HVT vec-
gle-dose vaccine approved in the EU to tor platform technology.”
provide combined protection against INNOVAX-ND-IBD-ILT can be admin-
diseases caused by Newcastle disease istered in the hatchery to layers and
virus, infectious bursal disease virus, breeder flocks to increase early-life Based on the CVMP’s recommenda-
infectious laryngotracheitis virus, and protection, and to broilers, both by sub- tion, the EC is expected to issue a deci-
Marek’s disease virus. The four dis- cutaneous injection (at day-old) or in sion for marketing authorization in the
eases addressed by INNOVAX-ND-IBD- ovo application (around 18 days of in- European Union (EU) during the third
ILT are amongst the most economically cubation). quarter of 2025. Circle 9 on enquiry card
8 Vol. 41 No. 5